Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

Completed · Not applicable · Has a placebo group

Conditions studied: Heart Failures

In brief

The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment. The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.

Key facts

Study ID

NCT01377987

Run by

David Andrew Wellman

People needed

29

Starts

2011-08-01

Expected to finish

2016-12-01

Last updated by the study team

2018-06-13

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• severe obstructive respiratory disease
• unstable heart failure status
• recent use of positive airway pressure therapy
• current use of opioids, benzodiazepines
• severe kidney disease
• severe anemia

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.